Cargando…

A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis

Simple models of therapy for viral diseases such as hepatitis C virus (HCV) or human immunodeficiency virus assume that, once therapy is started, the drug has a constant effectiveness. More realistic models have assumed either that the drug effectiveness depends on the drug concentration or that the...

Descripción completa

Detalles Bibliográficos
Autores principales: Conway, Jessica M., Perelson, Alan S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125050/
https://www.ncbi.nlm.nih.gov/pubmed/25101902
http://dx.doi.org/10.1371/journal.pcbi.1003769
_version_ 1782329714576195584
author Conway, Jessica M.
Perelson, Alan S.
author_facet Conway, Jessica M.
Perelson, Alan S.
author_sort Conway, Jessica M.
collection PubMed
description Simple models of therapy for viral diseases such as hepatitis C virus (HCV) or human immunodeficiency virus assume that, once therapy is started, the drug has a constant effectiveness. More realistic models have assumed either that the drug effectiveness depends on the drug concentration or that the effectiveness varies over time. Here a previously introduced varying-effectiveness (VE) model is studied mathematically in the context of HCV infection. We show that while the model is linear, it has no closed-form solution due to the time-varying nature of the effectiveness. We then show that the model can be transformed into a Bessel equation and derive an analytic solution in terms of modified Bessel functions, which are defined as infinite series, with time-varying arguments. Fitting the solution to data from HCV infected patients under therapy has yielded values for the parameters in the model. We show that for biologically realistic parameters, the predicted viral decay on therapy is generally biphasic and resembles that predicted by constant-effectiveness (CE) models. We introduce a general method for determining the time at which the transition between decay phases occurs based on calculating the point of maximum curvature of the viral decay curve. For the parameter regimes of interest, we also find approximate solutions for the VE model and establish the asymptotic behavior of the system. We show that the rate of second phase decay is determined by the death rate of infected cells multiplied by the maximum effectiveness of therapy, whereas the rate of first phase decline depends on multiple parameters including the rate of increase of drug effectiveness with time.
format Online
Article
Text
id pubmed-4125050
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-41250502014-08-12 A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis Conway, Jessica M. Perelson, Alan S. PLoS Comput Biol Research Article Simple models of therapy for viral diseases such as hepatitis C virus (HCV) or human immunodeficiency virus assume that, once therapy is started, the drug has a constant effectiveness. More realistic models have assumed either that the drug effectiveness depends on the drug concentration or that the effectiveness varies over time. Here a previously introduced varying-effectiveness (VE) model is studied mathematically in the context of HCV infection. We show that while the model is linear, it has no closed-form solution due to the time-varying nature of the effectiveness. We then show that the model can be transformed into a Bessel equation and derive an analytic solution in terms of modified Bessel functions, which are defined as infinite series, with time-varying arguments. Fitting the solution to data from HCV infected patients under therapy has yielded values for the parameters in the model. We show that for biologically realistic parameters, the predicted viral decay on therapy is generally biphasic and resembles that predicted by constant-effectiveness (CE) models. We introduce a general method for determining the time at which the transition between decay phases occurs based on calculating the point of maximum curvature of the viral decay curve. For the parameter regimes of interest, we also find approximate solutions for the VE model and establish the asymptotic behavior of the system. We show that the rate of second phase decay is determined by the death rate of infected cells multiplied by the maximum effectiveness of therapy, whereas the rate of first phase decline depends on multiple parameters including the rate of increase of drug effectiveness with time. Public Library of Science 2014-08-07 /pmc/articles/PMC4125050/ /pubmed/25101902 http://dx.doi.org/10.1371/journal.pcbi.1003769 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
spellingShingle Research Article
Conway, Jessica M.
Perelson, Alan S.
A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis
title A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis
title_full A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis
title_fullStr A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis
title_full_unstemmed A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis
title_short A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis
title_sort hepatitis c virus infection model with time-varying drug effectiveness: solution and analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125050/
https://www.ncbi.nlm.nih.gov/pubmed/25101902
http://dx.doi.org/10.1371/journal.pcbi.1003769
work_keys_str_mv AT conwayjessicam ahepatitiscvirusinfectionmodelwithtimevaryingdrugeffectivenesssolutionandanalysis
AT perelsonalans ahepatitiscvirusinfectionmodelwithtimevaryingdrugeffectivenesssolutionandanalysis
AT conwayjessicam hepatitiscvirusinfectionmodelwithtimevaryingdrugeffectivenesssolutionandanalysis
AT perelsonalans hepatitiscvirusinfectionmodelwithtimevaryingdrugeffectivenesssolutionandanalysis